12/18
08:30 am
govx
GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
Low
Report
GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
12/9
09:11 am
govx
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent [Yahoo! Finance]
Low
Report
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent [Yahoo! Finance]
12/9
09:00 am
govx
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
Low
Report
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
11/26
09:09 am
govx
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference [Yahoo! Finance]
High
Report
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference [Yahoo! Finance]
11/26
09:00 am
govx
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
Medium
Report
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
11/25
08:32 am
govx
GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
Low
Report
GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
11/19
09:14 am
govx
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia [Yahoo! Finance]
Low
Report
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia [Yahoo! Finance]
11/19
09:00 am
govx
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
Low
Report
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
11/15
08:04 am
govx
GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
11/13
02:26 am
govx
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges [Yahoo! Finance]
Medium
Report
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges [Yahoo! Finance]
11/12
04:00 pm
govx
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
11/12
08:18 am
govx
GeoVax Labs initiated with a Buy at Alliance Global Partners [Yahoo! Finance]
Medium
Report
GeoVax Labs initiated with a Buy at Alliance Global Partners [Yahoo! Finance]
11/11
07:47 am
govx
GeoVax Labs, Inc. (NASDAQ: GOVX) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $15.00 price target on the stock.
High
Report
GeoVax Labs, Inc. (NASDAQ: GOVX) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $15.00 price target on the stock.
11/5
09:00 am
govx
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
Low
Report
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024